Argos’ RNA-loaded dendritic cell vaccine technology has been validated
in numerous preclinical studies of tumor metastasis in animals as well
as in investigator-sponsored clinical trials in humans. These studies confirm
that the technology is not only safe and potent at inducing anti-tumor
responses in immunized patients, but also show encouraging clinical responses
in physician-sponsored small trials. These results will be validated in
larger company-sponsored trials, leading in some cases to fast-track registration.
Metastatic Renal Cell Carcinoma
total tumor RNA-loaded dendritic cell vaccine is currently in a corporate
Phase I/II clinical trial at clinical sites in the United
States and Canada. The trial focuses on patients with newly diagnosed metastatic
renal cell carcinoma. An additional objective of the trial includes demonstrating
the safety and commercial feasibility of processing dendritic cells at
a central manufacturing facility with delivery of the vaccine to multiple
For further information and eligibility criteria, refer to the National
Institutes of Health ClinicalTrials.gov website at
Argos is conducting preclinical research in a number of additional cancers
and expects to begin investigator-sponsored clinical trials using its RNA-loaded
dendritic cell vaccine in one or more of these cancers in the next six
to 12 months.
Other Therapeutic Areas
Argos is also conducting preclinical research in HIV and plans to begin
an investigator-sponsored clinical trial using its RNA-loaded dendritic
cell vaccine to treat HIV in 2005.